S&P 500   2,981.62 (+0.52%)
DOW   26,929.60 (+0.53%)
QQQ   192.25 (+0.61%)
AAPL   236.94 (+0.45%)
FB   186.50 (+1.76%)
MSFT   140.47 (+0.66%)
GOOGL   1,222.70 (+0.40%)
AMZN   1,742.80 (+0.37%)
CGC   19.87 (+5.36%)
NVDA   192.70 (+3.31%)
MU   45.32 (+1.00%)
GE   8.63 (-1.15%)
TSLA   255.86 (-0.43%)
AMD   30.36 (-0.56%)
T   37.60 (+0.32%)
F   8.93 (+1.25%)
ACB   3.73 (+6.27%)
PRI   121.90 (+0.35%)
NFLX   280.89 (-1.63%)
BAC   29.19 (+0.17%)
GILD   64.81 (+0.47%)
S&P 500   2,981.62 (+0.52%)
DOW   26,929.60 (+0.53%)
QQQ   192.25 (+0.61%)
AAPL   236.94 (+0.45%)
FB   186.50 (+1.76%)
MSFT   140.47 (+0.66%)
GOOGL   1,222.70 (+0.40%)
AMZN   1,742.80 (+0.37%)
CGC   19.87 (+5.36%)
NVDA   192.70 (+3.31%)
MU   45.32 (+1.00%)
GE   8.63 (-1.15%)
TSLA   255.86 (-0.43%)
AMD   30.36 (-0.56%)
T   37.60 (+0.32%)
F   8.93 (+1.25%)
ACB   3.73 (+6.27%)
PRI   121.90 (+0.35%)
NFLX   280.89 (-1.63%)
BAC   29.19 (+0.17%)
GILD   64.81 (+0.47%)
Log in

Celgene Stock Price, News & Analysis (NASDAQ:CELG)

$100.55
+0.16 (+0.16 %)
(As of 10/15/2019 10:03 AM ET)
Today's Range
$100.40
Now: $100.55
$100.73
50-Day Range
$93.99
MA: $98.40
$100.82
52-Week Range
$58.59
Now: $100.55
$100.96
Volume119,855 shs
Average Volume3.74 million shs
Market Capitalization$71.26 billion
P/E Ratio13.21
Dividend YieldN/A
Beta1.42
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.28 billion
Cash Flow$8.87 per share
Book Value$8.79 per share

Profitability

Net Income$4.05 billion

Miscellaneous

Employees8,852
Market Cap$71.26 billion
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.


Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has initiated a stock repurchase program on Thursday, May 24th 2018, which allows the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 5.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board of directors believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) posted its earnings results on Tuesday, July, 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $2.44 by $0.17. The biopharmaceutical company earned $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The company's quarterly revenue was up 15.4% on a year-over-year basis. During the same period last year, the company earned $2.16 earnings per share. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY20 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of > $12.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.45. The company issued revenue guidance of $19-20 billion, compared to the consensus revenue estimate of $19.18 billion.

What price target have analysts set for CELG?

18 analysts have issued 12 month price targets for Celgene's shares. Their predictions range from $77.00 to $112.00. On average, they expect Celgene's share price to reach $94.64 in the next twelve months. This suggests that the stock has a possible downside of 5.9%. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 16 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene’s lead drug, Revlimid, continues to drive revenues on label expansions and market share gains. Robust performance of psoriasis drug, Otezla, is also boosting performance. The focus is on the merger announcement with large-cap pharma Bristol-Myers worth a whopping $74 billion. Per the terms, Celgene shareholders will receive $50 plus one share of Bristol-Myers and one tradeable Contingent Value Right, which will entitle the holder to receive a cash payment of $9.00 upon the achievement of FDA approval of three candidates (ozanimod, liso-cel and bb2121) within the specified time periods. Meanwhile, the company is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. Shares have outperformed the industry in the year so far. Estimates are stable ahead of the second-quarter results." (7/23/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 12-month price target. Celgene reported a strong 4Q this morning and issued full year 2019 guidance. 4Q revs of ~$4B beat us and consensus on the top line, while adj. EPS of $2.39 also came in above us and consensus at $2.33 and $2.32. Base business trends were surprisingly strong, and management reiterated timelines for all five late- stage pipeline products on track for approval by the end of 2020. We think the key takeaway from the call was that commercial and pipeline execution appear to be back on track with a clear line of sight to the Bristol (BMY, NC) deal closing in 3Q19. We think guidance for 2019 seems conservative." (1/31/2019)

Has Celgene been receiving favorable news coverage?

News articles about CELG stock have trended very negative on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celgene earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Celgene.

Are investors shorting Celgene?

Celgene saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 11,215,900 shares, an increase of 5.7% from the July 31st total of 10,609,200 shares. Based on an average daily volume of 4,170,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 1.6% of the company's stock are short sold. View Celgene's Current Options Chain.

Who are some of Celgene's key competitors?

What other stocks do shareholders of Celgene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Akorn (AKRX), Gilead Sciences (GILD), NVIDIA (NVDA), Bank of America (BAC), Skechers USA (SKX), Integrated Device Technology (IDTI), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Intel (INTC).

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 60)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 50)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
  • Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhil, Pres of Research & Early Devel. (Age 54)
  • Dr. Alise Reicin M.D., Pres of Global Clinical Devel. (Age 58)

Who are Celgene's major shareholders?

Celgene's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.02%), Gulf International Bank UK Ltd (0.02%), Gofen & Glossberg LLC IL (0.02%), Havens Advisors LLC (0.02%), Artemis Investment Management LLP (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael D Casey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which institutional investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Gofen & Glossberg LLC IL, First Hawaiian Bank, Fulton Bank N.A., Welch & Forbes LLC, Bath Savings Trust Co, Crossmark Global Holdings Inc., YHB Investment Advisors Inc. and IMS Capital Management. Company insiders that have sold Celgene company stock in the last year include James J Loughlin and Terrie Curran. View Insider Buying and Selling for Celgene.

Which institutional investors are buying Celgene stock?

CELG stock was bought by a variety of institutional investors in the last quarter, including Alpine Group USVI LLC, State of Alaska Department of Revenue, Havens Advisors LLC, Pacer Advisors Inc., Anderson Hoagland & Co., Thomasville National Bank, Artemis Investment Management LLP and We Are One Seven LLC. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $100.62.

How big of a company is Celgene?

Celgene has a market capitalization of $71.31 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.View Additional Information About Celgene.

What is Celgene's official website?

The official website for Celgene is http://www.celgene.com/.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  1,992 (Vote Outperform)
Underperform Votes:  764 (Vote Underperform)
Total Votes:  2,756
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel